Pre-made Itolizumab benchmark antibody ( Whole mAb, anti-CD6/TP120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Itolizumab (INN, trade name Alzumab) is a "first in class" humanized IgG1 monoclonal antibody developed by Biocon and the Center of Molecular Immunology (CIM), Havana.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-284-1mg	1mg	3090
GMP-Bios-ab-284-10mg	10mg	Inquiry
GMP-Bios-ab-284-100mg	100mg	Inquiry
GMP-Bios-ab-284-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Itolizumab biosimilar, Whole Mab: Anti-CD6/TP120 therapeutic antibody
INN Name	Itolizumab
Target	TP120
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Center of Molecular Immunology;Biocon;Biotech Pharmaceutical;Equillium
Conditions Approved	Plaque psoriasis
Conditions Active	Graft-versus-host disease;Cytokine release syndrome;COVID-19;Asthma;Lupus nephritis
Conditions Discontinued	Autoimmune disorders;Multiple sclerosis;Psoriasis;Rheumatoid arthritis
Development Tech	na